Cyberdyne's CEJ Capital unit chipped into a round for the flu diagnostics device developer that hiked its overall funding to $27.5m.

A consortium of 15 startups were chosen to take part in the first edition of the internet technology group’s regional accelerator scheme, which will run until November this year.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from UT Southwestern with $30m.

Osage University Partners backed a round for Aerovate Therapeutics that will go to testing an inhaled version of the latter's pulmonary disease therapy.

Gene therapy developer Freeline Therapeutics priced an upsized offering at the top of its range following $275m in funding from investors including Novo.

Koch Industries and CK Hutchison both participated in a series D round that pushed the medical imaging system developer's total funding to more than $124m.

The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from stealth with $30m.

The mental healthcare app developer boosted its overall funding to $120m in a round that included Cigna Ventures and Kaiser Permanente Ventures.

Cigna and Kaiser Permanente have participated in a $50m series D round for Ginger, bringing the MIT spinout's total funding to more than $120m.